Cell Therapy in Myocardial Infarction (EMRTCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00350766

Recruitment Status : Terminated (Slow recruitment rate and consequent financial exhaustion.)

First Posted : July 11, 2006

Last Update Posted : March 30, 2017

Sponsor:

Collaborators:

Pro-Cardiaco Hospital

Hospital do Coracao

Instituto Estadual de Cardiologia Aloysio de Castro

Hospital Cardiológico Costantini

Hospital Universitário Regional do Norte do Paraná - FUEL

Hospital Santa Izabel

Hospital Santa Izabel de Sergipe

Hospital Agamenon

Hospital do Andaraí

Hospital de Messejana

Hospital de Clinicas de Porto Alegre

Faculty of Medicine of Ribeirão Preto (FMRP-USP)

Instituto Nacional de Cardiologia de Laranjeiras

Instituto de Cardiologia do Rio Grande do Sul

Hospital São Marcos

Hospital Universitário Oswaldo Cruz - UPE

Real Hospital Português de Beneficência

Hospital Municipal Miguel Couto

Anis Rassi Hospital, Brazil

Federal University of São Paulo

Instituto Dante Pazzanese de Cardiologia

Universidade Federal do Rio de Janeiro

Hospital Bandeirantes

InCor Heart Institute

Hospital Santa Isabel de Blumenau

Federal University of Uberlandia

Hospital TotalCor

Hospital de Clínicas Mario Lioni

Hospital de Clínicas de Niteroi

Information provided by (Responsible Party):

Hans Fernando Rocha Dohmann, Pro-Cardiaco Hospital

Study Description

Brief Summary:

The purpose of this study is to determine cell therapy efficacy in patients with ST elevation acute myocardial infarction (STEMI)

Condition or disease	Intervention/treatment	Phase
Acute Myocardial Infarction	Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation	Phase 2 Phase 3

Detailed Description:

This study protocol describes a randomized double blind clinical trial, which main purpose is to evaluate the effect of the autologous bone marrow mononuclear cell (ABMMC) implant in 300 Brazilian patients with ST elevation acute myocardial infarction (STEMI).

Double blind study design was chosen for this trial, based on several phase I and II safety trials of intracoronary autologous bone marrow stem cells transplantation, already published. The study coordinator committee, supported by the Brazilian Health Ministry, therefore has proposed a phase III trial with the purpose of proving the efficacy of this kind of therapy, for a population with a high risk of developing heart failure and of death by cardiovascular cause.

Thus, in this protocol we propose a prospective, double blind, controlled and randomized trial to evaluate the effect of ABMMC transplantation through intracoronary infusion, on systolic left ventricle (LV) function. The main hypothesis of this trial is that patients submitted to autologous bone marrow stem cell implant, after 6 months follow up, will present a 5% relative increase of the ejection fraction (EF) comparing to control group.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	166 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	Double Blind Randomized Controlled Trial
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:	Control group received injection of saline with 5% autologous serum without the suspension of mononuclear cells.
Primary Purpose:	Treatment
Official Title:	Multicenter Prospective Randomized Double Blind Trial of Bone Marrow Mononuclear Cells Transplantation Through Intracoronary Injection in Patients With Acute Myocardial Infarction.
Actual Study Start Date :	July 1, 2006
Actual Primary Completion Date :	January 21, 2014
Actual Study Completion Date :	July 14, 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Genetic and Rare Diseases Information Center resources: Acute Graft Versus Host Disease

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Treated Group Intracoronary injection in the infarcted-related artery of 100 million bone marrow mononuclear cells resuspended in a 10 ml solution of saline with autologous serum.	Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates. Other Name: Catheter based stem cell delivery
Placebo Comparator: Control Group Intracoronary injection in the infarcted-related artery of placebo solution consisting of a saline containing autologous blood serum.	Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates. Other Name: Catheter based stem cell delivery

Arm

Intervention/treatment

Experimental: Treated Group

Intracoronary injection in the infarcted-related artery of 100 million bone marrow mononuclear cells resuspended in a 10 ml solution of saline with autologous serum.

Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation

Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.

Other Name: Catheter based stem cell delivery

Placebo Comparator: Control Group

Intracoronary injection in the infarcted-related artery of placebo solution consisting of a saline containing autologous blood serum.

Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation

Other Name: Catheter based stem cell delivery

Outcome Measures

Primary Outcome Measures :

Global Left Ventricular Ejection Fraction change [ Time Frame: 6 months ]

Secondary Outcome Measures :

Death [ Time Frame: 30 days, 90 days, 6 months and 1 year ]
Acute myocardial infarction, stroke and hospital admission due to cardiovascular cause [ Time Frame: 30 days, 90 days, 6 months and 1 year ]
Reintervention of the AMI related artery and of the non-related artery [ Time Frame: 30 days, 90 days, 6 months and 1 year ]
Regional wall motion, wall thickening, and volume of late contrast enhancement [ Time Frame: Baseline and 6 months ]
Evolutive alterations of the coronarian anatomy, as well as the patency of the coronary stents [ Time Frame: 6 months ]
Quality of life assessment using the Short-Form 36, Minnesota Living with Heart Failure Questionnaire and Seattle Angina questionnaire [ Time Frame: Baseline, 6 months and 1 year ]
Cost-effectiveness and cost-utility evaluation of autologous bone marrow mononuclear cells implant versus conventional treatment [ Time Frame: 1 year ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	30 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients will be eligible if presenting all characteristics described below:
- ST segment elevation myocardial infarction in two or more contiguous leads, and according to the WHO definition, at least one of the following two:
  
  i) Presence of chest pain. ii) Elevation of the myonecrosis markers.
- Age between 30 and 80 years old.
- Ejection fraction ≤50% on Echocardiogram (Simpson) and segmentary dysfunction of the infarction area, measured between the 3rd and 5th day post AMI.

Among patients submitted to thrombolytic therapy, the angioplasty of the related artery should be preferably done up to 24h after thrombolysis, with a maximum deadline of 72h after thrombolysis.

Exclusion Criteria:

Patients will be ineligible if presenting any of the characteristics described below:
- AMI related artery presenting TIMI < 3 at the moment f cell injection.
- Left Main Coronary Artery Lesion of >50% or multivessel coronariopathy (>70% lesion in vessels with >2,0mm diameter in left anterior descending, circumflex and right coronary territory) indicating the need for CABG or angioplasty with three or more stents implant.
- Coronary anatomy, after thrombolytic reperfusion, presenting no need for angioplasty with stent implant.
- Final Diastolic Pression of the LV higher than 30 mmHg during ventriculography for evaluating EF inclusion criteria for the research protocol (item "c" of inclusion criteria).
- Cardiac arrest or Killip IV AMI at admission with need of ventilatory support.
- Cardiogenic shock persisting up to the third day after AMI (with need of Intra-aortic balloon pump or vasopressors).
- AMI mechanical complications (ventricular septal defect, papillary muscle rupture, and left ventricular free wall rupture).
- Significant valve disease, defined as aortic stenosis (mean systolic pressure gradient across the aortic valve >50mmHg), mitral stenosis with a valvar area less than 1,5 cm,2 moderate to severe aortic and/or mitral regurgitation.
- Chronic use of immunosuppressive agents.
- > 2,0 mg/dl creatinine or previous dialysis treatment.
- Presence of fever on the past 48h before injection glaring active systemic infection according to ACCP/SCCM (American College of Chest Physicians/Society of Critical Care Medicine) sepsis definition.
- Sustained ventricular tachycardia 48h after AMI.
- Illicit drugs abuse or alcohol abuse (based on DSM IV).
- Any co morbidity, with survival impact in two years.
- Myocarditis
- Active liver disease
- COPD in continuous steroids use.
- Hematological disease, neoplasm, bone disease or hemostatic disturbances.
- Inflammatory disease or chronicle infectious disease.
- Presence of definitive implantation of a cardiac pace maker or cardiac defibrillator.
- Impossibility to reach a cells suspension of 100 million mononuclear cells due to cells paucity in the bone marrow aspirate.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00350766

Locations

Layout table for location information

Brazil
PROCEP/Hospital Pró-Cardíaco
Rio de Janeiro, Brazil, 22280-000

Sponsors and Collaborators

Ministry of Health, Brazil